Back to Neurology
Neurologyv2014Evidence-Based

International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis

Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.

Clinical Input Parameters

pg/mL
pg/mL
pg/mL
Clinical Assessment
Awaiting Parameters
iwg2 diagnosis
—diagnosis
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within neurology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Diagnosis requires: Clinical AD phenotype (typical/atypical/mixed) + Pathophysiological biomarker evidence (CSF Aβ1-42 ↓ and/or T-tau ↑ and/or P-tau ↑ and/or Amyloid PET +). Topographical markers (MRI, FDG-PET) used for progression monitoring only.

Clinical Pearls & Practice Notes

  • The IWG-2 criteria were published in 2014 as revised research diagnostic criteria for AD
  • Core requirement: Clinical AD phenotype + pathophysiological biomarker evidence
  • Pathophysiological markers (diagnostic): CSF Aβ1-42, T-tau, P-tau, amyloid PET
  • Topographical markers (progression): volumetric MRI, FDG-PET (not used for diagnosis)
  • CSF Aβ1-42 inversely reflects brain amyloid burden (decreased = pathological)
  • CSF T-tau directly reflects neuronal degeneration intensity (elevated = pathological)
  • CSF P-tau is a direct marker of tau pathology (elevated = pathological)
  • Amyloid PET imaging provides in vivo assessment of brain amyloid plaques
  • Typical AD: Most common presentation with episodic memory impairment
  • Atypical AD: Non-amnestic presentations (e.g., posterior cortical atrophy, logopenic aphasia)
  • Mixed AD: AD pathology coexisting with other neurodegenerative processes
  • Asymptomatic at risk: Cognitively normal with positive amyloid biomarkers only
  • The criteria enable diagnosis across the full AD disease spectrum
  • Biomarker-supported diagnosis allows for earlier intervention
  • The framework facilitates research enrollment and clinical trial design
  • Progressive functional decline supports clinical significance
  • Criteria have been validated in multiple international cohorts
  • The IWG-2 approach has influenced other diagnostic frameworks (e.g., NIA-AA)
  • Regular reassessment may be needed as biomarkers evolve over time
  • Clinical judgment remains essential in applying these research criteria

Evidence & Literature Citations

  1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0.
  2. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
  3. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.

Score Interpretation Ranges

Typical ADtypical_ad – typical_ad pts

Meets criteria for typical Alzheimer's disease

Atypical ADatypical_ad – atypical_ad pts

Meets criteria for atypical Alzheimer's disease

Mixed ADmixed_ad – mixed_ad pts

Meets criteria for mixed Alzheimer's disease

Asymptomatic at Riskasymptomatic_at_risk – asymptomatic_at_risk pts

Asymptomatic at risk for Alzheimer's disease

Insufficient Criteriainsufficient_criteria – insufficient_criteria pts

Does not meet IWG-2 criteria for AD diagnosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.